Different types of antibodies to a brain receptor and their effects on thinking and brain protection
Effects of Different Isotypes of Anti-NMDAR1 Autoantibodies on Cognitive Function and Neuroprotection
This work looks at whether different naturally occurring antibodies that target an important brain receptor help or harm thinking, memory, and recovery after head injury in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11252320 on NIH RePORTER |
What this research studies
Researchers will measure levels of different anti‑NMDAR1 antibody types (like IgG, IgM, and IgA) in blood and compare those levels with performance on simple thinking and memory tests. The team will look at whether people with higher or lower levels of these antibodies report fewer symptoms after head injuries and perform better on cognitive tasks. The project builds on earlier findings that some antibody types may protect neurons while others can cause inflammation. Lab experiments will help explain how the different antibody types might affect brain cells and the blood‑brain barrier.
Who could benefit from this research
Good fit: Adults willing to give a blood sample and complete brief cognitive tests—especially people with a history of head injury or concerns about memory—would be appropriate candidates.
Not a fit: People with active, severe autoimmune encephalitis or those needing immediate clinical treatment are unlikely to get direct benefit from this observational and mechanistic work.
Why it matters
Potential benefit: If successful, this research could point to blood tests or antibody‑based strategies that protect memory and lessen damage after head injury.
How similar studies have performed: Prior animal studies show high IgG against NMDAR1 can cause brain inflammation while small human and animal data suggest some low‑level antibodies might protect neurons, so the approach builds on mixed but promising evidence.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Zhou, Xianjin — University of California, San Diego
- Study coordinator: Zhou, Xianjin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.